|
1
|
Adler S: Structure-function relationships
associated with extracellular matrix alterations in diabetic
glomerulopathy. J Am Soc Nephrol. 5:1165–1172. 1994.PubMed/NCBI
|
|
2
|
Mogensen CE, Christensen CK and Vittinghus
E: The stages in diabetic renal disease. With emphasis on the stage
of incipient diabetic nephropathy. Diabetes. 32(Suppl 2): S64–S78.
1983. View Article : Google Scholar
|
|
3
|
Leehey DJ, Singh AK, Alavi N and Singh R:
Role of angiotensin II in diabetic nephropathy. Kidney Int Suppl.
77:S93–S98. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lewis EJ, Hunsicker LG, Bain RP and Rohde
RD: The effect of angiotensin-converting-enzyme inhibition on
diabetic nephropathy. The Collaborative Study Group. N Engl J Med.
329:1456–1462. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Brenner BM, Cooper ME, de Zeeuw D, Keane
WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z and
Shahinfar S; RENAAL Study Investigators: Effects of losartan on
renal and cardiovascular outcomes in patients with type 2 diabetes
and nephropathy. N Engl J Med. 345:861–869. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gross ML, El-Shakmak A, Szábó A, Koch A,
Kuhlmann A, Münter K, Ritz E and Amann K: ACE-inhibitors but not
endothelin receptor blockers prevent podocyte loss in early
diabetic nephropathy. Diabetologia. 46:856–868. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Somlo S and Mundel P: Getting a foothold
in nephrotic syndrome. Nat Genet. 24:333–335. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ma L and Fogo AB: Role of angiotensin II
in glomerular injury. Semin Nephrol. 21:544–553. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fogo AB: Renal fibrosis and the
renin-angiotensin system. Adv Nephrol Necker Hosp. 31:69–87.
2001.PubMed/NCBI
|
|
10
|
Griendling KK and Ushio-Fukai M: Reactive
oxygen species as mediators of angiotensin II signaling. Regul
Pept. 91:21–27. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Swaminathan S and Shah SV: Novel
approaches targeted toward oxidative stress for the treatment of
chronic kidney disease. Curr Opin Nephrol Hypertens. 17:143–148.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hakim FA and Pflueger A: Role of oxidative
stress in diabetic kidney disease. Med Sci Monit. 16:RA37–RA48.
2010.PubMed/NCBI
|
|
13
|
Ha H, Yu MR and Kim KH: Melatonin and
taurine reduce early glomerulopathy in diabetic rats. Free Radic
Biol Med. 26:944–950. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Oktem F, Ozguner F, Yilmaz HR, Uz E and
Dündar B: Melatonin reduces urinary excretion of
N-acetyl-beta-D-glucosaminidase, albumin and renal oxidative
markers in diabetic rats. Clin Exp Pharmacol Physiol. 33:95–101.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang H, Zhang HM, Wu LP, Tan DX, Kamat A,
Li YQ, Katz MS, Abboud HE, Reiter RJ and Zhang BX: Impaired
mitochondrial complex III and melatonin responsive reactive oxygen
species generation in kidney mitochondria of db/db mice. J Pineal
Res. 51:338–344. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Elbe H, Vardi N, Esrefoglu M, Ates B,
Yologlu S and Taskapan C: Amelioration of streptozotocin-induced
diabetic nephropathy by melatonin, quercetin, and resveratrol in
rats. Hum Exp Toxicol. 34:100–113. 2015. View Article : Google Scholar
|
|
17
|
Kim EY, Alvarez-Baron CP and Dryer SE:
Canonical transient receptor potential channel (TRPC)3 and TRPC6
associate with large-conductance Ca2+-activated K+ (BKCa) channels:
Role in BKCa trafficking to the surface of cultured podocytes. Mol
Pharmacol. 75:466–477. 2009. View Article : Google Scholar
|
|
18
|
Lim AKh: Diabetic
nephropathy-complications and treatment. Int J Nephrol Renovasc
Dis. 7:361–381. 2014. View Article : Google Scholar :
|
|
19
|
Mundel P and Kriz W: Structure and
function of podocytes: An update. Anat Embryol (Berl). 192:385–397.
1995. View Article : Google Scholar
|
|
20
|
Faul C, Asanuma K, Yanagida-Asanuma E, Kim
K and Mundel P: Actin up: Regulation of podocyte structure and
function by components of the actin cytoskeleton. Trends Cell Biol.
17:428–437. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Endlich N, Kress KR, Reiser J, Uttenweiler
D, Kriz W, Mundel P and Endlich K: Podocytes respond to mechanical
stress in vitro. J Am Soc Nephrol. 12:413–422. 2001.PubMed/NCBI
|
|
22
|
Durvasula RV, Petermann AT, Hiromura K,
Blonski M, Pippin J, Mundel P, Pichler R, Griffin S, Couser WG and
Shankland SJ: Activation of a local tissue angiotensin system in
podocytes by mechanical strain. Kidney Int. 65:30–39. 2004.
View Article : Google Scholar
|
|
23
|
Anwar MM and Meki AR: Oxidative stress in
streptozotocin-induced diabetic rats: Effects of garlic oil and
melatonin. Comp Biochem Physiol A Mol Integr Physiol. 135:539–547.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lenz O, Elliot SJ and Stetler-Stevenson
WG: Matrix metalloproteinases in renal development and disease. J
Am Soc Nephrol. 11:574–581. 2000.PubMed/NCBI
|
|
25
|
Gumustekin M, Tekmen I, Guneli E, Tugyan
K, Topcu A, Ergonen AT, Ozdemir MH, Uysal N and Bediz CS:
Short-term melatonin treatment improved diabetic nephropathy but
did not affect hemorheological changes in diabetic rats. Pharmazie.
62:693–698. 2007.PubMed/NCBI
|
|
26
|
Ehrenberg B, Montana V, Wei MD, Wuskell JP
and Loew LM: Membrane potential can be determined in individual
cells from the nernstian distribution of cationic dyes. Biophys J.
53:785–794. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nicholls DG and Ward MW: Mitochondrial
membrane potential and neuronal glutamate excitotoxicity: Mortality
and millivolts. Trends Neurosci. 23:166–174. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kanwar YS, Wada J, Sun L, Xie P, Wallner
EI, Chen S, Chugh S and Danesh FR: Diabetic nephropathy: Mechanisms
of renal disease progression. Exp Biol Med (Maywood). 233:4–11.
2008. View Article : Google Scholar
|
|
29
|
Scott JA and King GL: Oxidative stress and
antioxidant treatment in diabetes. Ann N Y Acad Sci. 1031:204–213.
2004. View Article : Google Scholar
|
|
30
|
Brezniceanu ML, Liu F, Wei CC, Tran S,
Sachetelli S, Zhang SL, Guo DF, Filep JG, Ingelfinger JR and Chan
JS: Catalase overexpression attenuates angiotensinogen expression
and apoptosis in diabetic mice. Kidney Int. 71:912–923. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Durvasula RV and Shankland SJ: Activation
of a local renin angiotensin system in podocytes by glucose. Am J
Physiol Renal Physiol. 294:F830–839. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Stitt-Cavanagh E, MacLeod L and Kennedy C:
The podocyte in diabetic kidney disease. Scientific World Journal.
9:1127–1139. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Welsh GI and Saleem MA: Nephrin-signature
molecule of the glomerular podocyte? J Pathol. 220:328–337.
2010.
|
|
34
|
Adams JM and Cory S: Life-or-death
decisions by the Bcl-2 protein family. Trends Biochem Sci.
26:61–66. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hengartner MO: The biochemistry of
apoptosis. Nature. 407:770–776. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
36
|
Aaronson DS and Horvath CM: A road map for
those who don't know JAK-STAT. Science. 296:1653–1655. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chuang PY and He JC: JAK/STAT signaling in
renal diseases. Kidney Int. 78:231–234. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Quiroz Y, Ferrebuz A, Romero F, Vaziri ND
and Rodriguez-Iturbe B: Melatonin ameliorates oxidative stress,
inflammation, proteinuria and progression of renal damage in rats
with renal mass reduction. Am J Physiol Renal Physiol.
294:F336–F344. 2008. View Article : Google Scholar
|
|
39
|
Abkhezr M and Dryer SE: Angiotensin II and
canonical transient receptor potential-6 activation stimulate
release of a signal transducer and activator of transcription
3-activating factor from mouse podocytes. Mol Pharmacol.
86:150–158. 2014. View Article : Google Scholar : PubMed/NCBI
|
